Drug intelligence / Profile preview

mir-1298-5p mimic

Development stage
Preclinical
Modality
Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

mir-1298-5p mimic is a synthetic, double-stranded RNA oligonucleotide designed to replicate the biological activity of the endogenous microRNA miR-1298-5p. In the context of oncology, miR-1298-5p often functions as a tumor suppressor, and its downregulation is associated with cancer progression and chemoresistance. The mimic acts by binding to the 3' untranslated region (UTR) of specific target mRNAs, leading to translational inhibition or mRNA degradation. A primary target of miR-1298-5p is Karyopherin Subunit Alpha 4 (KPNA4), a protein involved in nuclear-cytoplasmic transport that is frequently overexpressed in malignant cells. By restoring miR-1298-5p levels, the mimic can counteract the effects of oncogenic circular RNAs (such as circ_0000376) that sequester endogenous miR-1298-5p, thereby inhibiting tumorigenesis and sensitizing cancer cells to treatments like paclitaxel.

Other names
hsa-miR-1298-5p mimichsa-miR1298-5p mimichsa-miR 1298-5p mimicmicroRNA-1298-5p mimicmicroRNA1298-5p mimicmicroRNA 1298-5p mimic
02

Targets

E2F1 (E2F Transcription Factor 1)MSH2 (DNA mismatch repair protein MSH2)SETD7 (SET domain containing lysine methyltransferase 7)KPNA4 (Karyopherin subunit alpha 3)

Beyond the preview

Go deeper on mir-1298-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mir-1298-5p mimic.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call